Agenus Inc. (NASDAQ:AGEN) Given Average Recommendation of “Hold” by Brokerages

Shares of Agenus Inc. (NASDAQ:AGEN) have been given a consensus recommendation of “Hold” by the six brokerages that are currently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $31.00.

Several equities analysts have recently commented on AGEN shares. Robert W. Baird lowered Agenus from an “outperform” rating to a “neutral” rating and cut their price target for the company from $35.00 to $8.00 in a research note on Friday, July 19th. Baird R W lowered Agenus from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 19th. StockNews.com began coverage on Agenus in a research note on Wednesday, April 17th. They issued a “hold” rating on the stock. HC Wainwright lowered Agenus from a “buy” rating to a “neutral” rating and cut their target price for the company from $40.00 to $9.00 in a research note on Thursday, July 18th. Finally, William Blair lowered Agenus from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 18th.

Agenus Trading Down 2.7 %

Shares of Agenus stock opened at $5.97 on Friday. The firm has a market cap of $125.27 million, a P/E ratio of -0.46 and a beta of 1.32. Agenus has a 12 month low of $4.78 and a 12 month high of $32.00. The stock’s fifty day moving average price is $13.98 and its 200-day moving average price is $12.60.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($3.04) EPS for the quarter, beating the consensus estimate of ($3.58) by $0.54. The firm had revenue of $28.01 million for the quarter, compared to analysts’ expectations of $40.70 million. Analysts forecast that Agenus will post -10.73 earnings per share for the current year.

Institutional Investors Weigh In On Agenus

Several institutional investors have recently added to or reduced their stakes in AGEN. Vanguard Group Inc. boosted its holdings in Agenus by 1.6% in the third quarter. Vanguard Group Inc. now owns 26,938,439 shares of the biotechnology company’s stock worth $30,440,000 after acquiring an additional 432,202 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in Agenus by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 107,019 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 27,137 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Agenus by 526.6% in the fourth quarter. SG Americas Securities LLC now owns 198,735 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 167,017 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in Agenus by 3,008.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company’s stock worth $1,909,000 after acquiring an additional 2,232,064 shares in the last quarter. Finally, Values First Advisors Inc. boosted its holdings in Agenus by 7.8% in the fourth quarter. Values First Advisors Inc. now owns 269,829 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 19,568 shares in the last quarter. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.